Our Team Sets Us Apart
We have extensive experience in all aspects of healthcare finance, including institutional sales, capital markets, investment banking, investor and public relations, sell-side analysis, and buy-side analysis. We have an equally strong foundation in the life sciences, which enables us to understand our client’s R&D, regulatory, and commercial strategy. The combination of financial service and life science expertise allow us to best serve our clients needs.
Andrew McDonald is a healthcare investment professional with expertise in identifying transformative medicines as well as in forecasting clinical trial, regulatory, and sales outcomes. Prior to co-founding LifeSci Advisors, Andrew most recently served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Co-head of Healthcare Research and Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer from 2000-2001.
Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
Michael Rice has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also a Managing Director at Think Equity Partners responsible for running Healthcare Capital Markets, where he was responsible for structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America for five years and was responsible for covering large hedge funds and private equity healthcare funds. Before joining BAC, he was also a Managing Director at JPMorgan/Hambrecht & Quist for eight years.
Michael Wood has been covering biotech and life science companies since the mid 1990s. He has experience as a sell-side analyst at Lehman Brothers, UBS and Hambrecht & Quist. On the buy-side, he spent four years working on a healthcare sector fund at Welch Capital Partners in New York. He has also acted as an independent advisor to venture capital firms on PIPE transactions and late stage private investments. Michael is a native of Dublin Ireland and holds an Honors Degree in Microbiology from Trinity College Dublin
Sharon Choe has been covering biotech and life science companies since 1993. She has experience as a buy-side analyst at UBS Asset Management for ten years covering the Biotech, Pharmaceutical, Medical Device and Healthcare Services sectors. She joined Credit Suisse Asset Management in 2003 where she covered the small cap healthcare sector and co-managed the global healthcare portfolio for two years, prior to joining BAM Capital. She holds a B.S. from Northeastern University.
Jerry Isaacson has broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Jerry has also worked as a Research Analyst for the Medical Technology Stock Letter. He brings a passion for science to his work and combines that with a deep interest in and knowledge of the biotech industry to constantly get at the important, underlying scientific questions that drive company valuations. Jerry holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.
Paul is an investor relations and corporate communications executive with 20 years of corporate and agency experience. Prior to joining LifeSci Advisors, Paul was responsible for directing investor relations for Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company that develops and commercializes a portfolio of oncology drugs. He was the architect of a proactive investor, media, and corporate communications program that ensured the Company’s vision, strategies, objectives and achievements were accurately and effectively communicated to Wall Street audiences. This contributed to a more than 23-fold growth in the Company’s market capitalization, from $40 million in October 2008 to more than $940 million in 2012. He successfully built active sell-side analyst coverage from two (2) to seven (7); Broadened the institutional shareholder base from 25% to more than 70% through proactive investor targeting; Secured invitations and managed investor outreach at 18 annual investor conferences; Managed an average of twelve (12) non-deal road shows per year; and, Placed stories in The Wall Street Journal, USA Today, Orange County Business Journal, TheStreet.com, and other media.
Prior to Spectrum, he led investor relations and corporate communications for NeoPharm, Inc., in suburban Chicago, Illinois. He was responsible for executing long-term investor, corporate, employee, and media relations programs designed to develop and refine core messages to optimize value creation, contributing to a more than 500% increase in market capitalization and a doubling of analyst coverage through several corporate events. Paul’s other investor relations and corporate communications experience includes Investor Awareness, Hill & Knowlton, Arlington Hospitality, and David A. Noyes & Company. Paul earned his MBA from the Lake Forest Graduate School of Management in Chicago, Illinois, as well as his Bachelor of Arts in Communications from Quincy University in Quincy, Illinois. He is also a NIRI-National and NIRI-Chicago chapter member, and a recent Officer of the NIRI-Orange County (California) chapter.
John Nugent has been a senior communications consultant for more than 20 years, primarily focused on healthcare and biotechnology companies in a broad range of development stages and therapeutic areas. He works closely with senior management teams providing skilled and knowledgeable IR and PR counsel. Previously John was Vice President of Corporate Communications and Investor Relations for BioCryst Pharmaceuticals and prior to that was Senior Vice President of Investor Relations at Burns McClellan, Inc. He holds a B.A. from Lake Forest College.